Combination therapy using low-dose doxepin for the improvement of sleep
AssigneesCurrax Pharmaceuticals LLC, ProCom One, Inc.
InventorsPhilip Jochelson, Robert Mansbach, Michael Skinner, Neil B. Kavey
Life of this patent
Estimating the term…
Abstract
A composition comprising doxepin, or a pharmaceutically acceptable salt, or prodrug thereof, and a compound that enhances sleep onset, sleep maintenance or reduces early morning awakenings. These compositions are useful for treating multiple manifestations of insomnia.
Claims19
A composition comprising doxepin, or a pharmaceutically acceptable salt or prodrug thereof, and one or more of a compound that promotes sleep onset.
A method of reducing a side effect of a sleep medication, comprising:
- identifying a patient suffering from a side effect caused by a non-doxepin sleep medication;
- providing the patient with doxepin in an amount of about 0.0001 to about 10 mg of doxepin, a pharmaceutically acceptable salt of doxepin, or a prodrug of doxepin;
- and
- providing the patient with the non-doxepin sleep medication in a dosage less than the dosage which causes the side effect when the medication is used as sleep therapy alone.
A composition comprising doxepin, or a pharmaceutically acceptable salt or prodrug thereof, and one or more of a compound that enhances gamma-aminobutyric acid (GABA) activity, a 5HT2a antagonist, a melatonin agonist, an ion channel blocker, a serotonin-2 antagonist/reuptake inhibitor (SARIs), a 5HT1a agonist, a GABA-B agonist and an orexin receptor antagonist.
Dependencies are inferred from the claim text.